摘要
既往认为胆固醇是动脉粥样硬化性心血管疾病(ASCVD)的致病危险因素,随着研究的深入,ASCVD不再被认为是单纯的动脉壁脂质堆积疾病,而可能是一种进展性炎症反应。本文通过回顾冠状动脉抗炎策略的发展,明确了“炎症学说”,复习小剂量秋水仙碱在冠心病应用的几个研究,进一步明确炎症治疗将为ASCVD的下一个管理靶点,管理炎症对降低心血管风险事件具有重要意义。
In the past,cholesterol was believed to be a pathogenic risk factor for ASCVD.With the deepening of research,ASCVD is no longer considered a simple arterial wall lipid accumulation disease,but may be a progressive inflammatory response.This article reviews the development of coronary artery anti-inflammatory strategies,clarifies the“inflammation theory”,reviews several studies on the application of low-dose colchicine in coronary heart disease,and further clarifies that inflammation treatment will be the next management target of ASCVD.Managing inflammation is of great significance in reducing cardiovascular risk events.
作者
李丽鹃
LI li-juan(Jinjiang Second Hospital,Quanzhou 362261,China)
出处
《海峡药学》
2024年第8期94-96,共3页
Strait Pharmaceutical Journal
关键词
炎症
减少炎症
秋水仙碱
C反应蛋白
ASCVD管理靶点
Inflammation
Reduce inflammation
Colchicine
C-reactive protein
ASCVD management targets
